Paid Clinical Trials Allentown

Discover 2,146 paid clinical trials in Allentown, Pennsylvania. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,146

A Study of EP0031 in Patients With Advanced RET-altered MalignanciesA Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting

PHASE1

PHASE2

Sponsor:

Ellipses Pharma

Location:

Philadelphia PA, New York NY, Washington DC, Fairfax VAshow 12 more

Code:

NCT05443126

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EP0031

A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Recruiting

PHASE3

Sponsor:

Boston Children's Hospital

Location:

Philadelphia PA, Wilmington DE, Hackensack NJ, New York NYshow 43 more

Code:

NCT05600426

Conditions

Severe Aplastic Anemia

Eligibility Criteria

Sex: All

Age: 0 - 25

Healthy Volunteers: Not accepted

Interventions

cyclosporine

Matched Unrelated Donor Hematopoetic Stem Cell Transplant

horse anti-thymocyte globulin (ATG)

rabbit anti-thymocyte globulin (ATG)

Methotrexate

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Recruiting

PHASE1

PHASE2

Sponsor:

BioInvent International AB

Location:

Philadelphia PA, Duarte CA

Code:

NCT04752826

Conditions

Advanced Malignancies

Ovarian Cancer

T-cell Lymphoma

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BI-1808

Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Recruiting

PHASE3

Sponsor:

Chimerix

Location:

Philadelphia PA, Summit NJ, New York NY, Neptune NJshow 53 more

Code:

NCT05580562

Conditions

H3 K27M

Glioma

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Dordaviprone (ONC201)

Dordaviprone (ONC201) + Placebo

Placebo

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Recruiting

PHASE2

Sponsor:

Immunovant Sciences GmbH

Location:

Summit NJ, Hagerstown MD, Duncansville PA, Cumberland MDshow 17 more

Code:

NCT06754462

Conditions

Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IMVT-1402

Placebo

Acupuncture for the Treatment of Interstitial Cystitis (IC) SymptomsAcupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms

Recruiting

PHASE3

Sponsor:

The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust

Location:

Philadelphia PA

Code:

NCT00094874

Conditions

Interstitial Cystitis

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Acupuncture

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Recruiting

PHASE1

Sponsor:

Genentech, Inc.

Location:

Philadelphia PA, New York NY, New Haven CT, Pittsburgh PAshow 10 more

Code:

NCT04449874

Conditions

Non-Small Cell Lung Cancer

Colorectal Cancer

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GDC-6036

Atezolizumab

Cetuximab

Bevacizumab

Erlotinib

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight InfantsPercutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting

Sponsor:

Nationwide Children's Hospital

Location:

Philadelphia PA, New York NY, Boston MA, Columbus OHshow 17 more

Code:

NCT05547165

Conditions

Ductus Arteriosus, Patent

Eligibility Criteria

Sex: All

Age: 7 - 32

Healthy Volunteers: Not accepted

Interventions

Percutaneous Patent Ductus Arteriosus Closure (PPC)

Responsive Management Intervention

Echocardiogram, cardiac

Efficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg PainEfficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg Pain

Recruiting

Sponsor:

Albert Einstein Healthcare Network

Location:

Elkins Park PA, Philadelphia PA, Seattle WA

Code:

NCT05296265

Conditions

Phantom Limb Pain

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

VR treatment for phantom limb pain

A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Recruiting

PHASE1

PHASE2

Sponsor:

Nuvalent Inc.

Location:

Philadelphia PA, New York NY, Washington DC, Fairfax VAshow 16 more

Code:

NCT05118789

Conditions

Locally Advanced Solid Tumor

Metastatic Solid Tumor

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

NVL-520